BRASKEM SA-CLASS A- ADR (BAK)
US1055321053 - ADR
We assign a fundamental rating of 1 out of 10 to BAK. BAK was compared to 84 industry peers in the Chemicals industry. Both the profitability and financial health of BAK have multiple concerns. BAK has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
BAK had negative earnings in the past year.
BAK had a negative operating cash flow in the past year.
In the past 5 years BAK reported 4 times negative net income.
Of the past 5 years BAK 4 years had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -5.12%, BAK is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
With a Return On Equity value of -93.87%, BAK is not doing good in the industry: 89.29% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -93.87% | ||
| ROIC | N/A |
ROA(3y)2.32%
ROA(5y)1.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BAK's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 2.66%, BAK is not doing good in the industry: 89.29% of the companies in the same industry are doing better.
BAK's Gross Margin has declined in the last couple of years.
BAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.66% |
OM growth 3Y-5.67%
OM growth 5Y-20.61%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.5%
GM growth 5Y-14.73%
2. Health
2.1 Basic Checks
BAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for BAK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
BAK has an Altman-Z score of 0.97. This is a bad value and indicates that BAK is not financially healthy and even has some risk of bankruptcy.
BAK has a Altman-Z score of 0.97. This is in the lower half of the industry: BAK underperforms 76.19% of its industry peers.
A Debt/Equity ratio of 10.77 is on the high side and indicates that BAK has dependencies on debt financing.
The Debt to Equity ratio of BAK (10.77) is worse than 96.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.77 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.97 |
ROIC/WACCN/A
WACC8.65%
2.3 Liquidity
BAK has a Current Ratio of 1.54. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.54, BAK is not doing good in the industry: 72.62% of the companies in the same industry are doing better.
BAK has a Quick Ratio of 1.03. This is a normal value and indicates that BAK is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.03, BAK is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.03 |
3. Growth
3.1 Past
The earnings per share for BAK have decreased strongly by -188.39% in the last year.
EPS 1Y (TTM)-188.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-388.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.43%
3.2 Future
Based on estimates for the next years, BAK will show a very strong growth in Earnings Per Share. The EPS will grow by 38.70% on average per year.
The Revenue is expected to grow by 6.97% on average over the next years.
EPS Next Y24.27%
EPS Next 2Y51.16%
EPS Next 3Y38.7%
EPS Next 5YN/A
Revenue Next Year9.15%
Revenue Next 2Y9.12%
Revenue Next 3Y6.97%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BAK. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 12.36, which indicates a correct valuation of BAK.
Based on the Price/Forward Earnings ratio, BAK is valued a bit cheaper than 69.05% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BAK to the average of the S&P500 Index (21.22), we can say BAK is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.36 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BAK is valued a bit more expensive than 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 15.89 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BAK's earnings are expected to grow with 38.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.16%
EPS Next 3Y38.7%
5. Dividend
5.1 Amount
BAK does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BRASKEM SA-CLASS A- ADR
NYSE:BAK (9/6/2024, 8:04:00 PM)
After market: 6.8 0 (0%)6.8
+0.29 (+4.45%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.71B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.36 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.12% | ||
| ROE | -93.87% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.77 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-188.39%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y24.27%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y